MX2021004582A - Compuesto 2-azabiciclo hexano inhibidor de jak. - Google Patents

Compuesto 2-azabiciclo hexano inhibidor de jak.

Info

Publication number
MX2021004582A
MX2021004582A MX2021004582A MX2021004582A MX2021004582A MX 2021004582 A MX2021004582 A MX 2021004582A MX 2021004582 A MX2021004582 A MX 2021004582A MX 2021004582 A MX2021004582 A MX 2021004582A MX 2021004582 A MX2021004582 A MX 2021004582A
Authority
MX
Mexico
Prior art keywords
jak inhibitor
compound
hexane compound
azabicyclo hexane
azabicyclo
Prior art date
Application number
MX2021004582A
Other languages
English (en)
Spanish (es)
Inventor
Paul R Fatheree
Lan Jiang
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2021004582A publication Critical patent/MX2021004582A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2021004582A 2018-10-29 2019-10-18 Compuesto 2-azabiciclo hexano inhibidor de jak. MX2021004582A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862751967P 2018-10-29 2018-10-29
PCT/US2019/056947 WO2020092019A1 (en) 2018-10-29 2019-10-18 2-azabicyclo hexane compound as jak inhibitor

Publications (1)

Publication Number Publication Date
MX2021004582A true MX2021004582A (es) 2021-06-15

Family

ID=68542755

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004582A MX2021004582A (es) 2018-10-29 2019-10-18 Compuesto 2-azabiciclo hexano inhibidor de jak.

Country Status (12)

Country Link
US (2) US10968222B2 (enExample)
EP (1) EP3853229A1 (enExample)
JP (1) JP2022506111A (enExample)
KR (1) KR20210084512A (enExample)
CN (1) CN112955451A (enExample)
AU (1) AU2019373059A1 (enExample)
BR (1) BR112021007788A8 (enExample)
CA (1) CA3113667A1 (enExample)
IL (1) IL282460A (enExample)
MX (1) MX2021004582A (enExample)
SG (1) SG11202103042XA (enExample)
WO (1) WO2020092019A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
CN111620868B (zh) * 2020-05-28 2021-08-31 爱斯特(成都)生物制药股份有限公司 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法
CN111973599A (zh) * 2020-08-07 2020-11-24 杭州邦顺制药有限公司 用于眼部疾病治疗的化合物
EP4196477A4 (en) * 2020-08-17 2024-10-09 Vyne Therapeutics Inc. TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS
EP4359402B1 (en) * 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
CN115969796B (zh) * 2022-12-06 2024-07-09 苏州大学 一种jak抑制剂长效微球及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
LT3001903T (lt) 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3371185T3 (da) * 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
UA123633C2 (uk) * 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2017077283A1 (en) * 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
HUE067145T2 (hu) 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途

Also Published As

Publication number Publication date
US10968222B2 (en) 2021-04-06
BR112021007788A2 (pt) 2021-07-27
JP2022506111A (ja) 2022-01-17
CN112955451A (zh) 2021-06-11
US20210206764A1 (en) 2021-07-08
AU2019373059A1 (en) 2021-05-06
KR20210084512A (ko) 2021-07-07
BR112021007788A8 (pt) 2022-04-26
IL282460A (en) 2021-06-30
SG11202103042XA (en) 2021-04-29
EP3853229A1 (en) 2021-07-28
CA3113667A1 (en) 2020-05-07
US20200131178A1 (en) 2020-04-30
WO2020092019A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
ZA201802496B (en) Jak kinase inhibitor compounds for treatment of respiratory disease
MX2022010795A (es) Hidrato cristalino de un compuesto inhibidor de jak.
PH12021550368A1 (en) Dimethyl amino azetidine amides as jak inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
MY199730A (en) Piperidine-substituted mnk inhibitors and methods related thereto
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
PH12021550388A1 (en) Process for preparing jak inhibitors and intermediates thereof
MX373102B (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
AU2018253590A1 (en) Imidazopyridazine compounds
MX2020002399A (es) Inhibidores del enlace proteína-proteína de wdr5.
MY199779A (en) Pyrrolopyrimidine compound and use thereof
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2020004588A (es) Inhibidor de proteasa de doble cabeza.
PH12022551012A1 (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.